Early Ileostomy Closure for Rectal Cancer Patients in North America

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18-90
SponsorJewish General Hospital

About this trial

Our preliminary work demonstrates that there is buy-in from both patients and surgeons with regards to early ileostomy closure (EIC) for select rectal cancer patients undergoing restorative proctectomy (RP) and diverting loop ileostomy (DLI). The feedback from leaders in Europe further supports the need for a large scale randomized-controlled trial (RCT) on this subject in North America. Should the results of such a study be favourable, we believe it could support a change in practice that would be beneficial to patients and the health care system alike. Furthermore, our work will help identify which patients and practices are suitable for EIC.

The goal of our project is to determine whether EIC in rectal cancer patients undergoing RP with a DLI is safe, feasible and beneficial in a North American population. Specifically, our primary objective is to compare the severity of complications between patients undergoing EIC versus traditional (late) closure. Our secondary objectives include assessing the difference in quality of life (QoL), early and late bowel function, and cost of care between these two groups.

Eligibility criteria

Qualifiers

Adult (≥18 years-old) patients

Underwent restorative proctectomy by a laparoscopic, robotic, transanal total mesorectal excision, or open approach with creation of a diverting loop ileostomy for the treatment of rectal cancer

Negative anastomotic "leak test" via CT scan with rectally-administered water-soluble contrast on post-operative day 7, 8 or 9.

Disqualifiers

Peri-operative immunosuppression (within 6 weeks of surgery date);

Age-adjusted Charlson Comorbidity Index >6;

Other major surgery during the index operation;

Any major complications (Clavien Dindo Grade III or greater) following restorative proctectomy;

Trial design

Treatments tested in this trial

  • Early Ileostomy Closure

Treatment groups

118 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Jewish General Hospital

Lead sponsor

McGill University Health Centre/Research Institute of the McGill University Health Centre

Collaborator